Knight Therapeutics (KHTRF) Expected to Announce Quarterly Earnings on Thursday

Knight Therapeutics (OTCMKTS:KHTRF) is anticipated to post its resultson Thursday, March 19th. Analysts expect Knight Therapeutics to post earnings of ($0.0029) per share and revenue of $118.1870 million for the quarter.

Knight Therapeutics Stock Performance

OTCMKTS KHTRF opened at $4.32 on Tuesday. The business’s 50 day moving average is $4.40 and its two-hundred day moving average is $4.37. Knight Therapeutics has a 12-month low of $3.79 and a 12-month high of $4.72.

Knight Therapeutics Company Profile

Knight Therapeutics Inc (OTCMKTS:KHTRF) is a specialty pharmaceutical company headquartered in Montreal, Canada, focused on acquiring, in-licensing and commercializing innovative branded products for the Canadian and Latin American markets. The company secures exclusive marketing and distribution rights to medicines across multiple therapeutic areas, including ophthalmology, pain management, hematology and women’s health. Its portfolio features both prescription pharmaceuticals and specialty products that address unmet patient needs through targeted treatments.

Operating primarily in Canada, Mexico and select Latin American countries, Knight has established strategic alliances with global pharmaceutical firms to introduce novel therapies at various stages of development.